Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | HTR1D | P28221 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.34 |
| ▸ | WNT3 | P56703 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442043 | 0.90 | HTR7 (0.48) | HTR7HTR1AHTR1DHTR2BDRD2 | |
| SCHEMBL4303618 | 0.89 | WNT3 (0.34) | HTR7HTR1AHTR1DHTR2BDRD2 | |
| SCHEMBL3442292 | 0.89 | HTR7 (0.36) | HTR7HTR1AHTR1DHTR2BDRD2 | |
| SCHEMBL3441475 | 0.86 | HTR7 (0.40) | HTR7HTR1AADRA1B | |
| SCHEMBL4297410 | 0.84 | HTR7 (0.37) | HTR7HTR1A | |
| SCHEMBL3409977 | 0.84 | HTR7 (0.37) | HTR7HTR1AHTR1DHTR2BDRD2 | |
| SCHEMBL4299091 | 0.83 | ALDH1A1 (0.35) | HTR7HTR1ADRD2DRD3 | |
| SCHEMBL3441500 | 0.79 | HTR7 (0.49) | HTR7HTR1AHTR1DHTR2BDRD2 | |
| SCHEMBL3442273 | 0.78 | HTR7 (0.48) | HTR7HTR1AHTR1DHTR2BDRD2 | |
| SCHEMBL3441795 | 0.78 | KCNQ1 (0.34) | SFRP1WNT3HCRTR1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | HTR7 939/4885HTR1A 372/4885HTR1D 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.